公开(公告)号：US20240166999A1

公开(公告)日：2024-05-23

申请号：US18424920

申请日：2024-01-29

Applicant: TOOLGEN INCORPORATED

Inventor： Eun Ji SHIN ,  Kang In LEE ,  Yu Ri CHOI ,  Hye Jung SHIN ,  Jae Young LEE ,  Hwan Yeul YU

IPC: C12N5/0775 ,  C12N9/16 ,  C12N15/11 ,  C12N15/86

CPC classification number: C12N5/0665 ,  C12N9/16 ,  C12N15/11 ,  C12N15/86 ,  C12N2310/20 ,  C12N2510/00 ,  C12Y301/00

Abstract: Mesenchymal stem cells, a preparation method therefor, and a cell therapeutic agent using same have hemocompatibility since thrombosis thereof is suppressed after the expression or activation level of blood coagulation initiating factor CD142 is reduced or inhibited. When intravascularly administered, the mesenchymal stem cells have improved hemocompatibility since thrombosis thereof, which can be caused by the administered mesenchymal stem cells, is suppressed.

公开(公告)号：US20240139254A1

公开(公告)日：2024-05-02

申请号：US18407597

申请日：2024-01-09

Applicant: TOOLGEN INCORPORATED

Inventor： Eun Ji SHIN ,  Kang In LEE ,  Yu Ri CHOI ,  Hye Jung SHIN ,  Jae Young LEE

IPC: A61K35/28 ,  C12N5/0775 ,  C12N9/22 ,  C12N15/113

CPC classification number: A61K35/28 ,  C12N5/0662 ,  C12N9/22 ,  C12N15/113 ,  C12N2310/20

Abstract: Provided are mesenchymal stem cells, a preparation method therefor, and a use thereof, the mesenchymal stem cell having oxidative stress resistance by reducing or inhibiting the expression or activity level of KEAP1, which is a negative regulator of Nrf2, so as to increase the activity of Nrf2.

公开(公告)号：US20250064861A1

公开(公告)日：2025-02-27

申请号：US18944148

申请日：2024-11-12

Applicant: TOOLGEN INCORPORATED

Inventor： Jae Young LEE ,  Chang Hyun AHN ,  Kang In LEE ,  Yu Ri CHOI

IPC: A61K35/39 ,  A61K35/407 ,  C12N5/071

Abstract: The present disclosure relates to cells for intravascular transplantation having hemocompatibility in which the blood coagulation mechanism and thrombosis reaction are inhibited by artificially modifying the F3 gene encoding CD142 that is an initiator of blood coagulation, using gene scissors technology to reduce or suppress the expression or activity of CD142, a method of producing the same, and a use thereof for preventing or treating liver disease and diabetes.

公开(公告)号：US20220204955A1

公开(公告)日：2022-06-30

申请号：US17606502

申请日：2019-04-26

Applicant: TOOLGEN INCORPORATED

Inventor： Joon Sun LEE ,  Min Hee JUNG ,  Yu Ri CHOI ,  Jeong Joon LEE

IPC: C12N9/22 ,  C12N15/11 ,  C12N15/88 ,  C12N15/85

Abstract: The present invention relates to an artificially engineered CRISPR/Cas9 system. More particularly, the present invention relates to an artificially engineered CRISPR enzyme having enhanced target specificity and a use of an artificially engineered CRISPR/Cas9 system including the same enzyme in genome and/or epigenome manipulation or modification, genome targeting, genome editing, and in vitro diagnosis, etc.